Actinium Pharmaceuticals Inc
ATNM
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.51M
Close$
$1.48
37.1% upside
Current Fair Value
37.1% upsideUndervalued by 37.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.51 Million |
|---|---|
| Enterprise Value | $-619,507.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.09 |
| Beta | 0.02 |
| Outstanding Shares | 31,399,086 |
Return
| Return on Equity | 37.32% |
|---|---|
| Return on Assets | 28.16% |
| Return on Invested Capital | 26.64% |
Valuation & Multiples
| P/E Ratio | 3.06 |
|---|---|
| PEG | -0.6 |
| Price to Sales | 1.08 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -0.02 |
| Enterprise Value to EBIT | -0.08 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -2.16 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$35.62 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$1.25 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 127,500▼ 19.05% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.97%▼ 0.37% |
|---|---|
| Total Invested | $5.27M▼ 28.32% |
| Investors Holding | 55▼ 7.00% |
ESG Score
No data
About Actinium Pharmaceuticals Inc
CEO: Sandesh Seth